Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Vanguard in Phase II with SmithKline Beecham anti-migraine compound, building portfolio via collaboration.

Executive Summary

VANGUARD MEDICA IN PHASE II WITH SMITHKLINE BEECHAM ANTI-MIGRAINE COMPOUND SB 209509, a selective 5HT1D receptor partial agonist. Guildford, England-based Vanguard Medica and SmithKline entered into a collaboration in November 1994 in which Vanguard agreed to develop SB 209509 for the U.S. and Europe, while SB retains worldwide marketing rights. Vanguard receives milestone payments, a share of future net operating receipts and co-promotion rights for the U.S. market.
UsernamePublicRestriction

Register

PS027499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel